

16 June 2025

EVE and TeleDocs Clinic Sign National Prescribing Agreement for Erectile Dysfunction Oral Soluble Film and Dysmenorrhea Gummy

Strategic clinic partnership will deliver online prescribing access and nationwide pharmacy support for EVE's oral health portfolio

- Agreement signed with TeleDocs Clinic for prescribing and education on a new oral soluble film to manage erectile dysfunction, and a gummy formulation to support women's health by managing dysmenorrhea
- TeleDocs Clinic will be the first online clinic authorised to prescribe both products
- Agreement strengthens EVE product launch plans and patient access ahead of anticipated regulatory approvals
- TeleDocs to provide promotional support, practitioner training, and digital reach for national rollout
- TeleDocs works with a network of over 3,500 pharmacies across Australia

EVE Health Group (ASX:EVE, EVE or the Company), is pleased to announce that its wholly owned subsidiary Nextract Pty Ltd has signed an agreement with TeleDocs Clinic & Consulting Pty Ltd (**TeleDocs**) for the online prescription and promotion of its lead pharmaceutical products: Libbo+ (oral soluble film for erectile dysfunction) and Dyspro (gummy format for dysmenorrhea).

Under the agreement, TeleDocs is the first telehealth provider appointed to prescribe both products to patients across Australia. TeleDocs will support practitioner education and product awareness via its network of over 3,500 pharmacies nationwide.

TeleDocs will work with EVE to develop decision support tools for practitioners and pharmacies, list the products onto major prescribing software platforms, and provide national exposure via newsletters and inclusion in professional education databases.

Additional collaboration initiatives include: (a) providing industry insights for practitioner education, (b) assisting in the development of practitioner and pharmacy-facing support tools, (c) supporting digital integration into prescribing software nationwide, (d) exploring potential weekly practitioner newsletters, and (e) listing the products on national education platforms.

Libbo+ and Dyspro are currently undergoing final-stage formulation and stability testing, with regulatory submissions and manufacturing expected in Q3/Q4 CY 2025.

Key terms of the agreement include:

- A two-year prescribing and marketing arrangement, effective immediately
- Obligations for TeleDocs to provide clinical training, digital education, and clinician engagement
- Product pricing terms to be determined and agreed between the parties prior to launch
- Quarterly reporting on prescribing activity and compliance
- Mutual commitments regarding branding integrity, confidentiality, and regulatory compliance
- Standard commercial provisions including termination or failure to agree on pricing terms

Commenting on the milestone, EVE Executive Director Stuart Gunzburg said:

“TeleDocs Clinic brings deep digital health expertise, a trusted prescribing platform, and a national footprint – all of which are critical to launching a new value proposition at scale, where there’s an unmet clinical need. This agreement strengthens our commercial readiness and ensures patients will be able to access treatment easily and safely through trusted healthcare channels.”

Authorised for release by the Board of Directors.

— ENDS —

Company enquiries

+61 8 6465 5500

info@evehealthgroup.com.au

About EVE Health Group

EVE Health Group (ASX: EVE) is an Australian-based health company developing and commercialising evidence-based wellness and pharmaceutical products. Through its subsidiaries Meluka Australia and Nextract EVE delivers science-led innovations designed to support consumer and practitioner health across retail, pharmacy and clinical channels.

For further information, please visit www.evehealthgroup.com.au and follow us on LinkedIn.